Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT005 open-label extension in mucopolysaccharidosis type VI
2026-525847-34-00Phase 2Authorised
- Sponsor
- Fondazione Telethon
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FT-005 in mucopolysaccharidosis type VI, sponsored by Fondazione Telethon. Primary endpoints: Incidence rate of dose-limiting toxicities and Urinary glycosaminoglycan response. Planned start Oct 2026; status: authorised.
02
Drugs
FT-005
03
Conditions
mucopolysaccharidosis type VI
Beyond the preview
Go deeper on 2026-525847-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525847-34-00.